Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of Arikace in cystic fibrosis with chronic Pseudomonas aeruginosa infection
2011-000442-38Phase 3Terminated
- Sponsor
- Insmed Incorporated
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection comparing Arikace with Placebo (2 arms). Primary endpoint: Time to first protocol defined pulmonary exacerbation. Started Jul 2011; status: terminated.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2011-000442-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000442-38.